https://www.selleckchem.com/pr....oducts/pi3k-hdac-inh
In a randomized pivotal global phase III study, S-1 and oxaliplatin 100mg/m (SOX10 combination chemotherapy was as effective as S-1 and cisplatin for advanced gastric cancer (AGC) and showed a favorable safety profile. In this phase II study, we analyzed survival outcomes to assess the efficacy and safety of the SOX regimen with oxaliplatin 130mg/m (SOX13 in AGC. Patients with HER2-negative AGC received 80mg/m /day S-1 orally on days 1-14 and 130mg/m oxaliplatin intravenously on day 1 of each 21-day cycle until the cri
Like
Comment
Share
